tiprankstipranks
Trending News
More News >

Kamada Launches Post-Marketing Research Program for CYTOGAM

Story Highlights
Kamada Launches Post-Marketing Research Program for CYTOGAM

Don’t Miss TipRanks’ Half-Year Sale

Kamada ( (IL:KMDA) ) just unveiled an announcement.

On May 5, 2025, Kamada Ltd. announced the launch of a comprehensive post-marketing research program for CYTOGAM®, aimed at generating key data to support its benefits in managing cytomegalovirus (CMV) in solid organ transplantation. The program will involve ten studies in collaboration with leading U.S. physicians, focusing on novel strategies for CMV management, alternative dosing, and potential new applications of CYTOGAM. This initiative underscores Kamada’s commitment to advancing CMV disease management and enhancing the understanding of CYTOGAM’s mechanism of action, potentially increasing its utilization in the coming years.

More about Kamada

Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies. The company’s portfolio includes FDA-approved products for rare and serious conditions, such as CYTOGAM®, KEDRAB®, GLASSIA®, and others. Kamada focuses on organic growth, business development, plasma collection expansion, and advancing new product candidates.

YTD Price Performance: 12.50%

Average Trading Volume: 208,179

Technical Sentiment Signal: Sell

Current Market Cap: $380M

See more data about KMDA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1